| Literature DB >> 27585556 |
Cheng Guo1, Xiaofen Li1, Rong Wang1, Jiekai Yu1, Minfeng Ye1,2, Lingna Mao1,3, Suzhan Zhang1, Shu Zheng1.
Abstract
Oxidative DNA damage plays crucial roles in the pathogenesis of numerous diseases including cancer. 8-hydroxy-2'-deoxyguanosine (8-OHdG) is the most representative product of oxidative modifications of DNA, and urinary 8-OHdG is potentially the best non-invasive biomarker of oxidative damage to DNA. Herein, we developed a sensitive, specific and accurate method for quantification of 8-OHdG in human urine. The urine samples were pretreated using off-line solid-phase extraction (SPE), followed by ultrahigh performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis. By the use of acetic acid as an additive to the mobile phase, we improved the UPLC-MS/MS detection of 8-OHdG by 2.7-5.3 times. Using the developed strategy, we measured the contents of 8-OHdG in urine samples from 142 healthy volunteers and 84 patients with colorectal cancer (CRC). We observed increased levels of urinary 8-OHdG in patients with CRC and patients with tumor metastasis, compared to healthy controls and patients without tumor metastasis, respectively. Additionally, logistic regression analysis and receiver operator characteristic (ROC) curve analysis were performed. Our findings implicate that oxidative stress plays important roles in the development of CRC and the marked increase of urinary 8-OHdG may serve as a potential liquid biomarker for the risk estimation, early warning and detection of CRC.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27585556 PMCID: PMC5009303 DOI: 10.1038/srep32581
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Effect of mobile-phase additives on the MS detection sensitivity of 8-OHdG.
The mobile phase consisted of solvents A and B (pure methanol). An isocratic elution of 92.5% A and 7.5% B was used, and the flow was set at 0.25 mL/min. The concentration of 8-OHdG standard was 20 nM, and the injection volume was 5.0 μL.
The peak area ratios of 8-OHdG obtained in different mobile phase A additives conditions.
| Mobile phase A additives | Peak area ratios | |
|---|---|---|
| MRM mode | Full scan mode | |
| 0.1% CH3COOH | 3.2 | 1.0 |
| 0.1% HCOOH | 1.2 | 0.7 |
| 2 mM NH4HCO3 | 1.0 | 0.4 |
| 2 mM HCOONH4 | 0.8 | 0.4 |
| 2 mM HCOONH4/HCOOH, pH = 3.5 | 0.6 | 0.5 |
| 2 mM HCOONH4/NH4OH, pH = 9.5 | 0.7 | 0.5 |
| 2 mM CH3COONH4 | 0.9 | 0.5 |
| 2 mM CH3COONH4/CH3COOH, pH = 5.0 | 0.9 | 0.8 |
| 2 mM CH3COONH4/NH4OH, pH = 9.0 | 0.7 | 0.6 |
aThe peak area ratios of 8-OHdG were obtained by other eight types of mobile phase vs mobile phase with NH4HCO3 as an additive.
bThe peak area ratios were calculated as peak area of [8-OHdG + H]+/(peak area of [8-OHdG + Na]+ + peak area of [8-OHdG + K]+).
Precision and accuracy for 8-OHdG QC samples at three different concentrations.
| Levels of 8-OHdG | |||
|---|---|---|---|
| LQC (10 nM) | MQC (50 nM) | HQC (200 nM) | |
| Intraday (n = 9) | |||
| Mean ± SD (nM) | 9.80 ± 0.18 | 50.55 ± 0.59 | 198.97 ± 2.06 |
| RSD (%) | 1.9 | 1.2 | 1.0 |
| Accuracy (%) | 98.0 | 101.1 | 99.5 |
| Interday (n = 3) | |||
| Mean ± SD (nM) | 9.85 ± 0.14 | 50.84 ± 0.73 | 199.52 ± 1.84 |
| RSD (%) | 1.4 | 1.4 | 0.9 |
| Accuracy (%) | 98.5 | 101.7 | 99.8 |
Recoveries of the off-line SPE-coupled UPLC-MS/MS obtained at three different spiking levels.
| Added amount of 8-OHdG (nM) | ||||
|---|---|---|---|---|
| 0 | 5 (low) | 20 (medium) | 60 (high) | |
| Mean ± SD (nM) | 18.70 ± 0.39 | 24.60 ± 0.53 | 39.08 ± 0.68 | 82.30 ± 1.04 |
| Average recovery (%) | — | 118.1 | 101.9 | 106.0 |
| RSD (%) | — | 3.3 | 2.4 | 1.9 |
Figure 2Identification of 8-OHdG in urine sample by UPLC-MS/MS.
(a) Representative chromatograms from human urine sample displaying internal standard [15N5]8-OHdG (m/z 289.1 > 173.0), 8-OHdG (m/z 284.1 > 168.0) and corresponding qualifier ion (m/z 284.1 > 117.0). (b) Representative chromatograms of internal standard and 8-OHdG standard.
Figure 3Quantification and statistical analysis of 8-OHdG in human urine samples.
(a) 8-OHdG content in healthy volunteers and patients with CRC. (b) 8-OHdG content in patients from stage I to IV. (c) 8-OHdG content in patients without (stage I and II) and with (stage III and IV) tumor metastasis. (d) ROC curve for urinary 8-OHdG score.
Logistic regression analysis of factors associated with CRC.
| Variable | Odds ratio | 95% CI | ||
|---|---|---|---|---|
| Urinary 8-OHdG concentration(nmol/mmol creatinine) | >1.5 | 3.68 | 1.82–7.45 | <0.0001 |
| ≤1.5 | 1 | — | — | |
| Age | 1.10 | 1.07–1.14 | <0.0001 | |
| Gender | Male | 0.58 | 0.28–1.18 | 0.111 |
| Female | 1 | — | — |